Herbalife

At its investor conference, Herbalife unveiled a strategy focused on stronger cash generation, further debt reduction and sustainable growth. In the second quarter the company reported net sales of $1.3 billion (+5.4%) and EBITDA of $167 million; for 2025 it expects revenue growth of 2.5–5.5% and a mid-point EBITDA of around $675 million. Gross debt has been reduced from $2.8 billion in 2021 to $2.0 billion; the target is gross debt of $1.4 billion and net debt of $1.0 billion by 2028. New growth drivers include acquisitions and platforms such as Bioniq, Prüvit, Link BioSciences and the digital Pro2col platform; Cristiano Ronaldo also invested in Pro2col and Bioniq. » Más en de.investing.com

Herbalife posted Q2 net sales of $1.3 billion, up 5.4% year over year, and adjusted EBITDA of $167 million, driven by strong growth in India, Asia Pacific and Latin America and a return to growth in North America while China and EMEA declined. The company launched personalized-nutrition offerings including Bioniq GO, expanded Pro2col testing, and introduced Helio and Activate Energy as it pushes its digital health strategy. Herbalife reported a GAAP net loss of $26 million largely from a $95 million pretax loss on debt extinguishment, but adjusted net income was about $53 million; operating cash flow for H1 was $147 million and net leverage was 2.2 times with a target below 2 times by year-end. Management raised the midpoint of constant-currency sales guidance for the year, provided Q3 and full-year EBITDA ranges, and announced CFO John DeSimone will retire at the end of 2026 with Scott Schaefer named successor. » Más en finance.yahoo.com

Herbalife reported Q2 net revenue of $1.33 billion (expected $1.31 billion) with adjusted earnings per share of $0.51 (expected $0.63); adjusted EBITDA was $167 million at the top end of the range. North America, Latin America and the Asia‑Pacific region showed strong growth, while EMEA declined 3.5% and China contracted 25%. Management raised the full‑year revenue outlook and highlighted initiatives in personalized nutrition as well as solid cash generation and a lower net leverage. The stock reacted negatively to the missed EPS and fell in after‑hours trading. » Más en de.investing.com